Literature DB >> 10545997

Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.

Y Li1, X C Li, X X Zheng, A D Wells, L A Turka, T B Strom.   

Abstract

The alloimmune response against fully MHC-mismatched allografts, compared with immune responses to nominal antigens, entails an unusually large clonal size of alloreactive T cells. Thus, induction of peripheral allograft tolerance established in the absence of immune system ablation and reconstitution is a challenging task in transplantation. Here, we determined whether a reduction in the mass of alloreactive T cells due to apoptosis is an essential initial step for induction of stable allograft tolerance with non-lymphoablative therapy. Blocking both CD28-B7 and CD40-CD40 ligand interactions (co-stimulation blockade) inhibited proliferation of alloreactive T cells in vivo while allowing cell cycle-dependent T-cell apoptosis of proliferating T cells, with permanent engraftment of cardiac allografts but not skin allografts. Treatment with rapamycin plus co-stimulation blockade resulted in massive apoptosis of alloreactive T cells and produced stable skin allograft tolerance, a very stringent test of allograft tolerance. In contrast, treatment with cyclosporine A and co-stimulation blockade abolished T-cell proliferation and apoptosis, as well as the induction of stable allograft tolerance. Our data indicate that induction of T-cell apoptosis and peripheral allograft tolerance is prevented by blocking both signal 1 and signal 2 of T-cell activation.

Entities:  

Mesh:

Year:  1999        PMID: 10545997     DOI: 10.1038/15256

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  143 in total

Review 1.  The tolerant recipient: looking great in someone else's genes.

Authors:  B R Rosengard; L A Turka
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Requirement for natural killer T (NKT) cells in the induction of allograft tolerance.

Authors:  K I Seino; K Fukao; K Muramoto; K Yanagisawa; Y Takada; S Kakuta; Y Iwakura; L Van Kaer; K Takeda; T Nakayama; M Taniguchi; H Bashuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

3.  Skin allograft maintenance in a new synchimeric model system of tolerance.

Authors:  N N Iwakoshi; T G Markees; N Turgeon; T Thornley; A Cuthbert; J Leif; N E Phillips; J P Mordes; D L Greiner; A A Rossini
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

Review 4.  New approaches to inducing the death of alloreactive lymphocytes.

Authors:  S M Krams
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

5.  Thymic re-entry of mature activated T cells and increased negative selection in vascularized allograft recipients.

Authors:  L A Chau; S Rohekar; J-J Wang; D Lian; S Chakrabarti; L Zhang; R Zhong; J Madrenas
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

6.  Differentiation of human alloreactive CD8(+) T cells in vitro.

Authors:  Rob J Rentenaar; Jelle L G Vosters; Frank N J van Diepen; Ester B M Remmerswaal; René A W van Lier; Ineke J M ten Berge
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

Review 7.  Challenges to achieving clinical transplantation tolerance.

Authors:  A D Salama; G Remuzzi; W E Harmon; M H Sayegh
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

8.  New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.

Authors:  Masayuki Sho; Sigrid E Sandner; Nader Najafian; Alan D Salama; Victor Dong; Akira Yamada; Koji Kishimoto; Hiroshi Harada; Isabela Schmitt; Mohamed H Sayegh
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 9.  PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.

Authors:  Myung-Ja Kwon; Ruiqing Wang; Jian Ma; Zuoming Sun
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-12       Impact factor: 2.895

10.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.